Match!
Paul Nathan
Northwood University
PathologyOncologyMelanomaTrametinibMedicine
176Publications
37H-index
9,536Citations
What is this?
Publications 174
Newest
#2Mohammed Abdul-Latif (NU: Northwood University)
Last. Sebastian HaferkampH-Index: 20
view all 19 authors...
Source
#1Georgina V. Long (USYD: University of Sydney)H-Index: 78
#2Celeste Lebbe (University of Paris)H-Index: 58
Last. Dirk SchadendorfH-Index: 102
view all 18 authors...
Source
#1Reinhard Dummer (UZH: University of Zurich)H-Index: 101
#2Kelly Biette (Novartis)
Last. Erika Richtig (Medical University of Graz)H-Index: 23
view all 20 authors...
Source
#1Jonathan Cebon (Ludwig Institute for Cancer Research)H-Index: 62
#1Jeffrey Evans (Glas.: University of Glasgow)H-Index: 8
Last. Duncan MacGregorH-Index: 33
view all 33 authors...
BACKGROUND: To compare the clinical efficacy of New York Esophageal squamous cell carcinoma-1 (NY-ESO-1) vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in a randomized, double-blind phase II study in participants with fully resected melanoma at high risk of recurrence. METHODS: Participants with resected stage IIc, IIIb, IIIc and IV melanoma expressing NY-ESO-1 were randomized to treatment with three doses of NY-ESO-1/ISCOMATRIX or ISCOMATRIX adjuvant administered intramuscularly at 4-...
Source
#1Pippa CorrieH-Index: 30
#2Andrea MarshallH-Index: 29
Last. Sarah DansonH-Index: 28
view all 38 authors...
Source
#1Paul Nathan (Mount Vernon Hospital)H-Index: 37
Source
#1Hannah Buckley (University of Leeds)H-Index: 2
#2F. Collinson (University of Leeds)H-Index: 12
Last. Naveen S. Vasudev (St James's University Hospital)H-Index: 18
view all 18 authors...
The combination of nivolumab, a programmed death-1 (PD-1) targeted monoclonal antibody, with the cytotoxic T-lymphocyte antigen-4 (CTLA-4) targeted antibody, ipilimumab, represents a new standard of care in the first-line setting for patients with intermediate- and poor-risk metastatic renal cell carcinoma (mRCC) based on recent phase III data. Combining ipilimumab with nivolumab increases rates of grade 3 and 4 toxicity compared with nivolumab alone, and the optimal scheduling of these agents w...
1 CitationsSource
#1J.-J. Grob (AMU: Aix-Marseille University)H-Index: 18
#2Victoria Atkinson (Greenslopes Private Hospital)H-Index: 24
Last. Axel HauschildH-Index: 18
view all 15 authors...
Source
#1Paul Nathan (NU: Northwood University)H-Index: 37
#1Paul Nathan (NU: Northwood University)H-Index: 1
Last. Joseph J. Sacco (University of Liverpool)H-Index: 9
view all 20 authors...
Source
#1Robert J. Motzer (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 103
#2Brian I. Rini (Cleveland Clinic)H-Index: 76
Last. Nizar M. Tannir (University of Texas MD Anderson Cancer Center)H-Index: 53
view all 39 authors...
Summary Background In the ongoing phase 3 CheckMate 214 trial, nivolumab plus ipilimumab showed superior efficacy over sunitinib in patients with previously untreated intermediate-risk or poor-risk advanced renal cell carcinoma, with a manageable safety profile. In this study, we aimed to assess efficacy and safety after extended follow-up to inform the long-term clinical benefit of nivolumab plus ipilimumab versus sunitinib in this setting. Methods In the phase 3, randomised, controlled CheckMa...
58 CitationsSource
12345678910